AS SEEN ON

 
About Us

Xerion Limited is an Australian-based consumer healthcare company focused on revolutionizing standard of care in dermatology through the development and commercialization of innovative therapies and diagnostics. Our nailKALM products are currently sold through pharmacies, podiatrists and online at nailKALM.com

Xerion Limited also has the exclusive commercial license to the PUFAcoatTM technology developed by Professor Robert Gibson and Dr Ge Liu of the School of Agriculture, Food and Wine, University of Adelaide, which has the ability to transform certain aspects of the personalised nutrition market. The technology allows simple, accessible, personalized determination of an individual’s fatty acid profile to help improve their health and achieve their wellness goals.  One application for this technology is its utility as a companion diagnostic tool for the high value consumer supplement market for which we have a distribution agreement with BASF, a global leader in fish oil production.

The company’s product portfolio includes proprietary algae bioactives and TGA approved anti-fungal products:

  • AMYCOT®: algal complex mix of bioactives with anti-fungal, anti-bacterial, anti-inflammatory and skin-repair properties.
  • KALM: Xerion’s lead product, a topical anti-fungal product line.
  • SKINACTIVÉ®: Xerion’s proprietary anti-aging and skin care cosmetic range.
  • PUFAcoat: a proprietary dried blood spot (DBS) which stabilises fatty acids for long periods of time in ambient conditions facilitating the accurate measurement of fatty acids and is a useful tool in determining the Omega 3 Index.

Xerion has a robust product pipeline and research partnerships to extend its product range and indications.

 
Directors & Management

The Company has a highly experienced Board of Directors and Management comprising the following personnel:

 

Oh Teik Tatt

Chairman

Mr Oh is currently Chairman and Partner of CEO solutions in Malaysia. He has extensive management and strategic board experience with several SE Asian companies and is currently on the board of AXA-Affin General Insurance.

Daniel Goldman

Managing Director

Experienced executive manager, having previously been General Manager Myer Stores Ltd and previously CFO and Company Secretary of Country Road.

Rodney Hannington

Non-Executive Director

Has over 25 years of experience working in Australia, Asia, Middle East & Africa, Russia and Ukraine markets with SPRIM, Kraft Foods (and Novartis. Headed Novartis Anti Fungal Division in Asia Pacific.

George Su Su

Non-Executive Director

Mr Su headed CITIC Securities Australian Operation between 2009 and 2013 with special focus on cross border transactions between Australia and China. Mr Su serves on ASX listed boards including Oriental Technology Investment Co Ltd and YPB Group.

Dr Leodevico (Vic) Ilag

Chief Scientific Officer

More than 20 years of biotech experience in the discovery and development of biologics and diagnostics serving in multiple senior executive roles in R&D and business development with several biotech companies in Australia and Europe.

Sharyn Cunningham

Chief Finance Officer

Sharyn is an experienced Chartered Accountant with both large public and small company experience. She has previously worked with Shell Australia and Grant Thornton

 
Partners

partners_slim21basf

 
Technology

AMYCOT®

Xerion’s first bioactive ingredient is AMYCOT®, an antimicrobial extract derived through a proprietary process from the microalgae Arthrospira maxima, that has a number of activities including:

  • anti-fungal (specific action against a major structural component of fungi cell walls)
  • anti-bacterial (against gram positive bacteria)
  • anti-viral (against Papilloma and Herpes simplex viruses)
  • anti-inflammatory
  • skin repair

AMYCOT® may therefore be regarded as a product platform and the first products to be commercialised are based primarily on AMYCOT®’s fungicidal activity under the brand Calmagen® with additional anti-inflammatory and skin repair benefits.

1. Parekh M et al. (2017) A pilot single centre, double blind, placebo controlled, randomized, parallel study of Calmagen® dermaceutical cream and lotion for the topical treatment of tinea and onychomycosis. BMC Complementary and Alternative Medicine 17:464. DOI 10.1186/s12906-017-1970-2

2. Ilag LL (2018) AMYCOT®,a Novel Natural Treatment for Ringworm and other Tinea Infections. Journal of Dermatology and Clinical Research 6(1):1114

PUFAcoat

Xerion has acquired the exclusive license in Australia and a number of other countries to the PUFAcoat technology from world leading lipids and nutrition researcher Prof Robert Gibson of the FOODplus Research Centre at the University of Adelaide.

The PUFAcoat protection system comprises a combination of protectants on a defined collection matrix. PUFAcoat can protect against the oxidation of long chain polyunsaturated fatty acids (LCPUFA) in blood spots at ambient temperature for at least 2 months. PUFAcoat was found to prevent any significant loss in the level of the two most important omega 3 fatty acids, EPA and DHA, in blood spots following up to 2 months of storage at room temperature.

1. Ge L et al. (2014) A method for long term stabilisation of long chain polyunsaturated fatty acids in dried blood spots and its clinical application. Prostaglandins, Leukotrienes and Essential Fatty Acids 91:251–260. http://dx.doi.org/10.1016/j.plefa.2014.09.009
A validated method for analyzing polyunsaturated

2. Ge L et al.(2015) Evaluation of contamination associated with current blood spot technology for determining the fatty acid status of individuals. European Journal of Lipid Science and Technology 117(8):1280-1286. https://doi.org/10.1002/ejlt.201400470

3. Hewawasam E et al. (2017) A validated method for analyzing polyunsaturated free fatty acids from dried blood spots using LC–MS/MS. Prostaglandins, Leukotrienes and Essential Fatty Acids 125:1-7. http://dx.doi.org/10.1016/j.plefa.2017.08.010.
A method for long term stabilisation of long chain

4. Carmel T Collins et al (2017) Docosahexaenoic Acid and Bronchopulmonary Dysplasia in Preterm Infants. New England Journal of Medicine 376:1245-1255. DOI:!10.1056/NEJMoa1611942 Docosahexaenoic Acid and Bronchopulmonary Dysplasia in Preterm Infants

5. Hewawasam E et al. (2018) Estimation of the Volume of Blood in a Small Disc Punched From a Dried Blood Spot Card. European Journal of Lipid Science and Technology 120(3): 1700361(1-6). https://doi.org/10.1002/ejlt.201700362
Estimation of the Volume of Blood in a Small Disc

Bioactive New Product Development (NPD) Platform

Xerion’s Bioactive NPD platform integrates different generic and proprietary technologies from the discovery of bioactives through clinical validation up to a new marketable product.

In addition to Xerion’s existing product range within the marketplace, the Company will be developing new product initiatives that aim to improve the quality of life of people, world-wide.

Ilag LL (2018) Botanicals and its extracts: A new drug discovery and development paradigm for chronic and age-related illnesses. Medical Research and Innovations 1(1):1-3. doi: 10.15761/MRI.1000131
 
News

Coming soon

 
Product Pipeline

Table

KALM

Anti-Fungal Range

The KALM® range of anti-fungal products comprises: a cream, lotion, and powder all of which are Listed Medicines with the Australian TGA.

Current product range

  • KALM SkinKALM Dermaceutical Cream
    20g Tube – Aust L 148907
  • KALM SkinKALM Dermaceutical Cream
    25ml Oval Flask – Aust L 148907
  • KALM SkinKALM Dermaceutical Cream
    40g Talc Drum – Aust L 148907

skinactive_footer

Anti-Ageing Skincare

Our SKINCARE RANGE® range of skincare products will use our unique anti-inflammatory and anti-ageing proprietary technology supported by scientific research.

Product range could include being developed.

  • Soothing Facial Cream cleanser
  • Soft Hydrating Facial Mask
  • Anti-Ageing Renewal Serum
  • Anti-Ageing Revitalising cream with SPF 15
  • Anti-Ageing Rejuvenation Night Cream
  • Facial exfoliant
  • Anti-Ageing Toner
  • Anti-Ageing Revitalising Eye Cream
  • Anti-Ageing Hand cream
  • Anti-Ageing Foot cream
  • Range of Acne products

pufacoat_footer

Dried Blood Spot Technology

Dried Blood Spot Technology (PUFAcoat): Revolutionary precision Dried Blood Spot technology that accurately measures fatty acids in blood and other biological fluids.

Current product range includes:

  • Only DBS that accurately measures fatty acids in blood and other biological fluids
  • Currently being used in numerous clinical trials
  • Ready to market directly to consumers
 
Contact





captcha


HEAD OFFICE ADDRESS: 246 Esplanade Brighton VIC 3186 Australia
HEAD OFFICE PHONE: + 61 3 9553 8896